Literature DB >> 3665989

Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512).

L M Ching1, B C Baguley.   

Abstract

Flavone acetic acid (FAA), an antitumour drug at present undergoing clinical trial for cancer treatment, has been found to activate natural killer cell activity in spleen cells of mice following in vivo treatment at doses of 45-330 mg/kg. The activity of FAA was measured using a 51Cr-release assay, employing the YAC-1 lymphoma line as a target cell population, and was found to be comparable to that of the interferon inducer polyinosinic acid-polycytidylic acid. The induction of activity was blocked by anti-asialo GM1 antibody. The time course of induction of activity by FAA was similar to that of the induction of haemorrhagic necrosis of the colon 38 tumour in mice, suggesting that natural killer cells or other components of the immune system may be involved in the action of FAA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665989     DOI: 10.1016/0277-5379(87)90357-9

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  26 in total

1.  Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells.

Authors:  G Damia; G Tagliabue; P Allavena; M D'Incalci
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Flavone acetic acid and plasma protein binding.

Authors:  J Brodfuehrer; F Valeriote; K Chan; L Heilbrun; T Corbett
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512).

Authors:  M C Bibby; R M Phillips; J A Double
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.

Authors:  I N Olver; L K Webster; J F Bishop; K H Stokes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.

Authors:  M de Forni; G G Chabot; J P Armand; A Gouyette; M Klink-Alak; G Recondo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 6.  Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours.

Authors:  J Cummings; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.

Authors:  M J McKeage; P Kestell; W A Denny; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.

Authors:  L M Ching; M J McKeage; W R Joseph; P Kestell; L J Zwi; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Species-specific detection of the antiviral small-molecule compound CMA by STING.

Authors:  Taner Cavlar; Tobias Deimling; Andrea Ablasser; Karl-Peter Hopfner; Veit Hornung
Journal:  EMBO J       Date:  2013-04-19       Impact factor: 11.598

10.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.